45 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28245354	5	Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.	Merck
27816515	143	Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.	Merck
27994755	18	Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.	Merck
27106707	98	Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.	Merck Research Laboratories
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
25915084	4	Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.	Genentech
25998502	8	Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.	Acelot
25625541	58	Overcoming mutagenicity and ion channel activity: optimization of selective spleen tyrosine kinase inhibitors.	Merck
25791676	26	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation.	University of Sydney
25415535	118	Inhibitors of c-Jun N-terminal kinases: an update.	Eberhard Karls Universit£T T£Bingen
25353650	111	Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.	Pfizer
25113930	63	Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.	Pfizer
25219901	19	Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.	Technische Universit£T Darmstadt
24354345	34	Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.	Genentech
24900590	55	Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.	Glaxosmithkline
24044867	86	Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.	Califia Bio
23768909	50	Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.	Novartis Institutes For Biomedical Research
23721803	6	The development of CNS-active LRRK2 inhibitors using property-directed optimisation.	The University of Sydney
23454015	54	Triazolopyridazine LRRK2 kinase inhibitors.	Elan Pharmaceuticals
23453068	25	Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.	Elan Pharmaceuticals
23219325	36	Novel cinnoline-based inhibitors of LRRK2 kinase activity.	Elan Pharmaceuticals
24900567	21	Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.	Genentech
22863203	1	GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.	Glaxosmithkline
22985112	49	Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.	Genentech
22591441	29	Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.	Genentech
23066449	3	Brain Penetrant LRRK2 Inhibitor.	TBA
24900536	3	Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.	TBA
22335897	2	Characterization of TAE684 as a potent LRRK2 kinase inhibitor.	University of Dundee
22056746	53	Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.	Boehringer Ingelheim Pharmaceuticals
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
28408230	13	Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.	Charles River Discovery Research Services
28225601	23	Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.	Stony Brook University
11927256	30	Insight into binding of calyculin A to protein phosphatase 1: isolation of hemicalyculin a and chemical transformation of calyculin A.	The University of Tokyo
18540668	56	Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.	Boehringer Ingelheim Pharmaceuticals
15723556	4	Use of binding enthalpy to drive an allosteric transition.	University of Maryland